$4.49
3.13% yesterday
Nasdaq, Oct 30, 02:30 pm CET
ISIN
US44975P1030
Symbol
IMAB

I-Mab - ADR Stock price

$4.95
+1.17 30.95% 1M
+4.01 426.60% 6M
+4.10 482.35% YTD
+3.88 362.62% 1Y
+1.24 33.42% 3Y
-34.98 87.60% 5Y
-7.55 60.40% 10Y
-7.55 60.40% 20Y
Nasdaq, Closing price Fri, Oct 31 2025
+0.40 8.79%
ISIN
US44975P1030
Symbol
IMAB
Industry

Key metrics

Basic
Market capitalization
$366.7m
Enterprise Value
$200.7m
Net debt
positive
Cash
$166.0m
Shares outstanding
188.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
1.9
Financial Health
Equity Ratio
94.4%
Return on Equity
-11.0%
ROCE
-18.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-160.7m
EBIT
$-37.4m | $-38.7m
Net Income
$-37.7m | $-31.6m
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
-100.0% | -
EBITDA
- | -216.8%
EBIT
70.2% | 24.1%
Net Income
56.7% | -43.8%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.2
FCF per Share
-
Short interest
4.0%
Employees
32
Rev per Employee
$0.0
Show more

Is I-Mab - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

I-Mab - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a I-Mab - ADR forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a I-Mab - ADR forecast:

Buy
92%
Hold
8%

Financial data from I-Mab - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 24 24
46% 46%
-
- Research and Development Expense - -
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -37 -37
70% 70%
-
Net Profit -38 -38
57% 57%
-

In millions USD.

Don't miss a Thing! We will send you all news about I-Mab - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

I-Mab - ADR Stock News

Neutral
GlobeNewsWire
2 days ago
New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX) Consistent with the new hub-and-spoke busines...
Neutral
GlobeNewsWire
9 days ago
ROCKVILLE, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), is a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide, today announced that updated data from the Phase 1 study (NCT04900818) of givastomig as a monotherapy in heavily pre-treated patients (n=45) with gastroesophageal carcinoma (GEC)...
Neutral
Seeking Alpha
14 days ago
I-Mab (NASDAQ:IMAB ) Discusses Business Transformation Strategy and Plans for Accelerated Growth October 16, 2025 5:00 PM EDT Company Participants Xi-Yong Fu - CEO & Director Wei Fu - Executive Chairman Emmett T. Cunningham Kyler Lei Conference Call Participants PJ Kelleher Daina Graybosch - Leerink Partners LLC, Research Division Christopher Liu - Lucid Capital Markets, LLC, Research Division ...
More I-Mab - ADR News

Company Profile

I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company's product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia and cancer immunotherapy; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for cancer treatment; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Head office Cayman Islands
CEO Xi-Yong Fu
Employees 32
Founded 2016
Website www.i-mabbiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today